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Exosomes are membrane-bound nanovesicles that are shed by cells of various lineages under normal as well as
pathological conditions. Previously thought to be ‘extracellular debris’, exosomes have recently generated immense
interest following their discovery as mediators of intercellular communication by delivering functional proteins,
mRNA transcripts as well as miRNAs to recipient cells. Although suggested to primarily serve as signaling organelles
which also remove unwanted cellular components in the brain, accumulating evidence suggests that exosomes can
also significantly contribute to the development of several neuropathologies. Toxic forms of aggregated proteins such
as α-synuclein, amyloid β and prions, that are responsible for the development of Parkinson’s disease, Alzheimer’s
disease and Creutzfeldt-Jacob disease (CJD) respectively, have been shown to get effectively packaged into exosomes
and spread from one cell to another, initiating an inflammatory cascade. In addition, exosomes secreted by resident
brain cells in response to pathogenic stimuli such as viral proteins can also influence bystander cells by the transfer of
dysregulated miRNAs that suppress the expression of essential genes in the recipient cells. Given the relevance of
exosomes in brain communication and neuropathogenesis, novel therapeutic strategies are now being developed
that exploit the biology of these vesicles to deliver anti-inflammatory molecules to the CNS. Exosomes may alter
the way we think about brain disorders and their treatments.
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Disorders of the central nervous system (CNS) can arise
from a variety of etiologies including neurodegeneration,
autoimmunity and infection. Although several mecha-
nisms have been implicated, one common player capable
of mediating the pathogenesis of these diseases has re-
cently emerged. Exosomes are spherical, membrane-bound
nanovesicles that are shed by a majority of cell types in the
body. They are released under normal as well as patho-
logical conditions and mediate intercellular communica-
tion between cells of various lineages. Initially thought to
be waste bags that carried unwanted proteins shed by cells,
exosomes were only recently discovered to contain not
only cellular proteins but also mRNA transcripts as well as
miRNA from the host cell. Importantly, exosomes can to
be internalized by cells of various lineages and functionally
alter the physiological environment of the recipient cell.
These observations quickly changed the perception of exo-
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article, unless otherwise stated.for cell communication. The past few years have witnessed
a deluge of information in the field of extracellular vesicles
and their implications to not only serve as potential bio-
markers of several diseases, but also as a mechanism for
the development of many pathological conditions. The
information unraveled thus far is just the tip of the
iceberg. The discovery of exosomes as extracellular
vesicles packed with functional cellular cargo bears the
potential to significantly influence the future of diag-
nostics and drug delivery. This review focuses on the
current knowledge of exosomes in the pathogenesis
of various CNS disorders, their potential to serve as
therapeutic agents to treat neuroinflammation as well
as biomarkers to diagnose various brain diseases.Exosome biogenesis
Exosomes are 30 to 100 nm spherical vesicles that are
released in to the extracellular space by diverse cell types
and mediate a variety of cellular functions [1,2]. Similar
to microvesicles, exosomes also transport a host of bio-
molecules to cells of different lineages [3-7]. Together,
they are often referred to as extracellular vesicles and
can be distinguished not only by their size, but also byentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
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Gupta and Pulliam Journal of Neuroinflammation 2014, 11:68 Page 2 of 10
http://www.jneuroinflammation.com/content/11/1/68the source of their origin. In contrast to microvesicles
that are shed by the plasma membrane [7,8], exosomes
are formed by the inward budding of the limiting mem-
brane of the late endosome, and encapsulate cellular
proteins, RNA as well as miRNAs from the cytoplasm in
a non-random fashion [9,10]. Late endosomes that are
packed with several such small vesicles (or intraluminal
vesicles) are often termed multivesicular bodies (MVBs).
The late endosomes are destined to either fuse with the
lysosome which leads to the degradation of the contents
of the vesicles, or the plasma membrane which allows
for the exosomes to be released into the extracellular
space. The formation of the intraluminal vesicles is a
regulated process that involves the organization of the
endosomal membrane into specialized domains that are
highly enriched for a specific class of membrane proteins
called tetraspanins (Figure 1). These units, also called
Tetraspanin-Enriched Membrane Domains (TEMs) re-
cruit proteins required to facilitate vesicular fusion and/
or fission [11]. Additionally, the TEMs also recruit
potential ligands for receptor-mediated internalization of
the exosome by the recipient cell [12]. Several members
of the tetraspanin family including CD9, CD63 and
CD81 are highly enriched on exosomal membranes and
not surprisingly, serve as marker proteins for the vesi-
cles. A second set of proteins involved in the formationFigure 1 Composition of exosomes. Exosomes and microvesicles are me
Exosomes are 30 to 100 nm in size and packed with a variety of cellular
selectively packaged from the cell the vesicles are shed. The exosome m
presentation called major histocompatibility complexes (MHC I and II), tar
(annexins and Rab proteins) as well as lipid-rafts.of the exosomes are the components of the ESCRT
machinery (Endosomal Sorting Complex Required for
Transport). Membrane proteins that are signaling-induced
ubiquitinated and internalized into early endosomes trig-
ger the recruitment of the ESCRT complexes. ESCRT
complexes 0, I, and II directly bind to ubiquitin, and there-
fore, allow only those proteins that are ubiquitinated to be
loaded onto MVBs. However, there are a few exceptions
in which proteins that are not ubiquitinated are also
sorted into these vesicles; in such instances, sorting is
believed to be a passenger effect [13].
In addition, ESCRT I, and II are suggested to drive the
budding of the intraluminal vesicles (ILV), while ESCRT
III is required for the cleavage of the bud to form the
ILV. Another important protein, Alix, that is also often
used as an exosomal marker and interacts with TSG101
and CHMP4, participates in several processes of the exo-
some biogenesis including cargo packaging and vesicle
formation.
Composition of exosomes
Exosomes are lipid-bilayer enclosed vesicles that carry
cellular proteins, mRNA as well as miRNAs. The mem-
brane proteins appear in the same orientation as on the
cell membrane, owing to two invaginations, one at the
surface of the plasma membrane, during the formationmbrane-bound extracellular vesicles secreted from various cell types.
components including mRNAs, miRNAs and proteins that are often
embrane is decorated with various proteins involved in antigen
geting and adhesion (integrins and tetraspanins), membrane trafficking
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of the endosomal membrane. Considering that the for-
mation of exosomes is an active process, there are several
membrane proteins and lipids that are unique to these
vesicles compared to the cell surface. Owing to their
endosomal origin, exosomes harbor tetraspanins (CD9,
CD63, CD81 and CD82), proteins required for membrane
transport and fusion (annexins, Rab proteins, flotillin),
proteins associated with MVB biogenesis (Alix, TSG101),
and heat shock proteins (Hsc70, Hsp90) as previously
reviewed [8,14] (Figure 1). The vesicles also carry a variety
of cytoskeletal proteins (actin, tubulin, profilin, cofilin, and
so on) and metabolic enzymes (GAPDH and pyruvate
kinase). Additionally, the exosomal membrane is enriched
with lipid-rafts including cholesterol, sphingolipids, cer-
amide and glycerophospholipids containing long and satu-
rated fatty-acyl chains. Interestingly, exosomes secreted
from antigen-presenting cells such as dendritic cells also
exhibit functional major histocompatibility complexes
(MHC I and II) on their surface [15,16].
The cell type the exosome is derived from heavily
influences the protein content of the exosomes. Several
proteomic studies performed on exosomes isolated from
cancerous cells reveal the presence of various factors
associated with tumor progression such as metastasis,
angiogenesis and signal transduction [17]. The exosomal
pathway can also be hijacked by viruses to spread viral
proteins to other cell types, without actually infecting
them, and dysregulating their function. For instance,
CD4+ T cells infected by HIV release the viral protein
Nef in exosomes which induces apoptosis of bystander
T cells [18].
Exosomes are highly enriched in small RNAs. A
bioanalyzer profile of exosomal RNA indicates that the
predominant RNA species in these vesicles ranges from
4 to 40 nucleotides in length [19], consistent with miR-
NAs. An increasing body of evidence suggests that exo-
somal miRNA is functional in the recipient cell and can
repress the expression of the target genes in the latter
[4,20-22]. The ability of such miRNAs to exert a bio-
logical effect indicates that they are stable as well as
associated with cellular proteins that render them func-
tional. Several studies show that exosomal miRNAs are
in fact associated with Ago2 proteins, albeit to various
degrees [23]. MVBs are proposed to be a site for the
congregation of miRNA pathway components, mature
miRNAs as well as the target transcripts [24], and may
therefore be the route for the packaging of these ele-
ments into exosomes. Apart from cellular miRNAs, spe-
cific virus-encoded miRNAs can also be packaged into
exosomes of infected cells. Epstein-Barr virus (EBV) has
been shown to encode viral miRNAs BHRF1 and BART
that can be shed in nanovesicles from infected B-cells
and suppress the immunoregulatory gene CXCL11 innon-infected neighboring monocyte-derived dendritic cells
[25]. In addition, HIV-encoded trans-activation response
element (TAR)-miRNA can be released by infected cells in
nanovesicles, influencing the susceptibility to infection of
cells that internalize it [26]. Clearly, viruses have evolved
strategies to usurp the host exosomal machinery in order
to propagate and attenuate host antiviral response.
mRNA transcripts, also enclosed in exosomes, can be
readily translated to proteins by the cell receiving the
vesicles. Valadi et al. [27] were among the first to dem-
onstrate that exosomal mRNA from mouse cells could
be translated into murine proteins by human mast cells.
However, the majority of these transcripts appear to be
highly enriched in the 3′-untranslated regions, suggest-
ing that the mRNA in these vesicles may play more of a
regulatory rather than a functional role [28].
Uptake of exosomes is an energy-dependent active
process [4,29]. Various proteins and lipids present on
the exosomal membrane such as tetraspanins and phos-
phatidylserine take part in receptor-mediated endocyto-
sis by interacting with their complementary molecules
present on the plasma membrane of the target cell
[29,30] and initiate internalization. The endocytic path-
way involved in exosomal uptake however varies from
cell-to-cell. Although phagocytosis is the major pathway
for exosome internalization by professional phagocytic cells
such as liver Kupffer cells and dendritic cells [30,31], up-
take of vesicles by macropinocytosis has also been demon-
strated for the brain resident macrophages, microglia [32].
In contrast, non-phagocytic cells employ both clathrin-
dependent [29] and independent endocytic pathways [33]
to internalize exosomes.Exosomes in CNS communication
Most cells in the CNS, including neurons, astrocytes,
oligodendrocytes and microglia shed exosomes. These
extracellular vesicles are secreted by neural cells under
both normal and pathological conditions and have been
isolated not just from the cerebrospinal fluid [34] but
also from adult human brain [35]. The suggested roles
of exosomes in CNS are to get rid of waste membrane
and cellular materials, and to serve as messengers for
communication between neural cells. In that regard,
exosomes can participate not only in the development of
the CNS, but also in regulating synaptic activity as well
as regeneration following injury. For instance, maturing
neurons regulate oligodendrocyte differentiation by exert-
ing an effect on the release of oligodendrocyte-derived
autoinhibitory exosomes [36]. In contrast, exosomes re-
leased from oligodendrocytes in response to glutamate
activation can influence neuronal metabolism and exhibit
neuroprotective function by the functional transfer of
oligodendrocyte cargo [37].
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enable signal transduction from one neuron to the next
by the transfer of chemical messages, inducing changes
in second messengers that trigger a response leading to
transmission of the signal. Exosomes shed by different
neural cells can participate in synaptic excitation by
transferring essential proteins for neurotransmission to
neurons. Synapsin, a synaptic vesicle-associated protein
implicated in neural development was shown to be
released by glial cells in exosomes under conditions of
high neuronal activity or cell stress [38]. These exosomes
increase neuronal survival and promote neurite growth
under adverse environmental conditions. Microglial cells
can also stimulate synaptic activity in neurons via exo-
somes [39]. Microglial exosomes enhance ceramide and
sphingosine metabolism in the recipient neurons result-
ing in an increase in neurotransmission.
Exosomes can mediate neuroprotection. Astrocytes,
known primarily to provide nutritional support to neu-
rons, secrete elevated levels of heat shock protein 70
(Hsp70) in response to oxidative stress and hyperthermia
[40] by increasing the survivability of neighboring neurons
during injury [41]. In the peripheral nervous system,
Schwann cells communicate with and support axonal
regeneration after nerve damage through exosomes. The
exosomes mediate such effect, at least in part by theFigure 2 Exosomal cross talk from the periphery and within the centr
Inflammation in the periphery can lead to neural cell impairment by virtu
macrophages traffic across the blood-brain barrier (BBB) at a high frequen
including dysregulated miRNAs, mRNAs and proteins as well as microbial by-
transfer the neurotoxic cargo to astrocytes and neurons causing neurodysfun
exosomes. The release and uptake of exosomes by various cell types in the b
enriched in heat shock proteins that serve a neuroprotective function du
hand, promote neurotransmission by stimulating ceramide and sphingos
support to neurons in response to glutamate activation while neuronal esuppression of the activity of RhoA, a GTPase activated in
response to injury and inhibiting axonal regeneration at
growth cones [42] (Figure 2).
Exosomes and neuroinflammatory disorders
While exosomes mediate several vital processes required
for normal brain functioning [37,39,42], they are also
involved in the pathogenesis of many neuroinflammatory
disorders, both infectious [20,43] and neurodegenerative
in nature [44-46]. Increasing evidence suggests that
exosomes serve as carriers to misfolded and pathogenic
proteins [43,47], initiating or propagating the disease in
neighboring cells. In addition to cytoplasmic proteins,
aberrantly expressed cellular miRNAs, selectively packaged
and transported in exosomes to neural cells [19,35], can
further dysregulate gene expression of the recipient cell.
Exosomes in the pathogenesis of infectious CNS diseases
HIV-associated neurocognitive disorders (HAND)
HIV infection is associated with an elevated risk for
neurological impairment. Abuse of drugs such as opiates
during infection further increases the incidence and pro-
gression of HIV-associated neurodysfunction, although
the mechanism for the synergistic effect remains un-
known. A recent study by Hu et al. [20] suggested that
co-exposure of astrocytes to morphine and HIV Tatal nervous system (CNS). (A) Influence of peripheral inflammation.
e of activated monocyte-derived exosomes. Activated monocyte/
cy and shed exosomes that can harbor pathogenic cellular products
products. Once internalized by neural cells, exosomes can functionally
ction. (B) Normal intercellular communication in the brain mediated by
rain is part of normal brain communication. Astrocytes release exosomes
ring stress conditions. Exosomes shed by microglia, on the other
ine syntheses. Oligodendrocyte-derived exosomes offer metabolic
xosomes regulate differentiation of the former.
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29b which can impair neuronal function. The mechanism
involves the functional transfer of miR-29b to neurons
leading to the suppression of the neuroprotective protein
platelet-derived growth factor (PDGF)-B expression. The
expression of PDGF is also suppressed, and coupled to
elevated levels of miR-29b, in the basal ganglia of the
brains of simian immunodeficiency virus-infected ma-
caques dependent on morphine, underscoring the pos-
sibility of exosomes mediating the neuropathology.
HIV-infected cells can also release the TAR RNA pack-
aged into exosomes [26]. These exosomes are proposed
to increase the susceptibility of the recipient cells, such
as astrocytes, to HIV infection by the interference of
host gene expression caused by 3′TAR-miRNA.
Prion disease Prion diseases are infectious neurodegen-
erative disorders associated with the accumulation of an
abnormally folded isoform of the prion protein (PrP),
scrapie (PrPSc), considered as the infectious agent. The
misfolded protein can induce conformational conversion
of cellular prion protein into its pathogenic isoform by a
protein-only template-directed mechanism. The disease,
often fatal in nature includes CJD in humans, scrapie in
sheep, and bovine spongiform encephalopathy in cows.
It is characterized by massive neuronal loss leading to
the formation of large spongiform vacuoles in the brain.
Although conditioned media from prion-infected neu-
rons can spread infection to uninfected cells, the mech-
anism for such dissemination remained elusive for many
years. A pioneering study by Fevrier et al. [43] demon-
strated that PsPSc associates with neuronal exosomes,
thereby bypassing the need for cell-to-cell contact. Inter-
estingly, these exosomes were shown to infect not only
uninfected recipient cells but also non-neuronal cells [47].
Exosome-associated PrP is processed by a distinct path-
way that involves N-terminal modification of the protein
and selective loading of PrP glycoforms for incorporation
into the vesicles [47].
Another significant observation in regard to the role of
exosomes in the pathogenesis of prion disease was made
by Bellingham and colleagues [19]. They demonstrated
that exosomes secreted by prion-infected neuronal cells
have significantly altered miRNA content including
elevated expression of several miRNAs associated with
neurological disorders such as miRs-29b, 128a and 146a.
Alteration of exosomal miRNA content can influence the
functioning of the recipient cell by dysregulating the
expression of potentially important genes.
Exosomes and neurodegeneration
Alzheimer’s disease (AD) AD is the most common
form of age-associated dementia in humans [48]. It is
characterized by accumulation of extracellular amyloidβ (Aβ) plaques and intracellular neurofibrillary tangles of
hyperphosphorylated tau protein that ultimately leads to
slow and progressive loss of neurons. The Aβ peptide is
formed by the sequential proteolytic cleavage of the
transmembrane amyloid precursor protein (APP) by two
membrane-bound enzymes β-secretase and γ-secretase.
Although several different species of Aβ peptides are
generated, the longer forms are particularly hydrophobic
and prone to aggregation in extracellular Aβ plaques [49].
The tau protein, on the other hand, is a microtubule-
stabilizing protein that is predominantly expressed in
neurons and regulates axonal transport. Hyperphosphory-
lation of tau leads to its dissociation from microtubules
and aggregation into insoluble fibers in neurons.
The roles of exosomes in mediating the pathogenesis
of AD were initially associated with the nanovesicles
serving as vehicles for the transport of the Aβ peptides
to the extracellular environment. A seminal study by
Rajendran et al. [44] demonstrated that the cleavage of
APP by β secretase occurs in a specific subset of endo-
somes and is trafficked into MVBs from where it is
released in association with exosomes. Interestingly, exo-
somal proteins such as Alix and flotillin-1 are found to
accumulate around amyloid plaques in the brains of AD
patients further underscoring the relevance of exosomes
in spreading Aβ [44]. Recently, amyloid peptides were
shown to induce apoptosis in astrocytes by up-regulating
the intracellular expression of the proapoptotic proteins,
prostate apoptosis response 4 (PAR4) and ceramide [45].
Importantly, astrocytes exposed to the Aβ peptides could
induce apoptosis in bystander astrocytes by the release of
exosomes enriched in PAR4 and ceramide, suggesting that
the vesicles could either functionally transfer the proteins
to the recipient astrocytes or trigger a cascade of events
ultimately leading to cell death. In addition to Aβ pep-
tides, exosomes also carry phosphorylated tau protein
associated with neurodegeneration [50] and may be re-
sponsible for cell-to-cell spread of tau as has been re-
ported previously [51]. Exosome-associated phosphotau is
readily detected at elevated levels in the cerebrospinal
fluid (CSF) samples of early AD patients and decreases as
the disease progresses despite the increase in the overall
level of the protein, possibly due to dissociation of tau
from the exosome fraction.
Parkinson’s disease After AD, Parkinson’s disease (PD)
is the most common neurodegenerative disorder affecting
nearly 1% of the population over 50 years old [52]. Pa-
tients suffering from PD typically demonstrate movement-
related disorders such as resting tremor, and muscle
rigidity and cognitive malfunction as the disease progresses.
Elevated intracellular levels of aberrant conformations of
α-synuclein (α-Syn), a presynaptic neuronal protein,
areAccepted frequently associated with PD pathology.
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volved in transporting α-Syn to the extracellular envir-
onment and spreading the toxic oligomers to naïve
neurons [53]. Uptake of exosomes loaded with α-Syn
has been shown to induce cell death in healthy neurons
[46] further highlighting the potential of exosomes in the
pathogenesis of neurodegenerative disorders. In addition
to neurons, other cell types including astrocytes [54] have
also been shown to internalize α-Syn deposits released by
pathologic neurons. The phenomenon is associated with
the formation of inclusion bodies in the latter, as observed
in the brains of PD patients [54] as well as initiation of an
inflammatory response. Another interesting perspective to
the role of exosomes in PD pathogenesis comes from the
reports that mutations in several genes involved in the
endocytic pathway such as leucine-rich receptor kinase 2
(LRRK2), and vacuolar sorting protein 35 (VPS35), are
linked to PD [52]. LRRK2, for example, has been shown to
regulate synaptic transmission and its overexpression is
associated with suppression in synaptic vesicle endocytosis
and exocytosis in neurons [55]. Additionally, a mutation
in LRRK2 leads to an abnormal increase in the number of
morphologically distinct MVBs [56]. Formation of a large
number of MVBs could potentially lead to the accumula-
tion of exosomes enriched in the toxic form of α-Syn and
spread the disease to neighboring cells upon release.
Impact of peripheral inflammation on the CNS via
exosomes
Often, conditions associated with inflammation in the
periphery impact brain function. For instance, untreated
HIV infection is associated with neurocognitive impair-
ment in over 50% of infected subjects [57,58]. Coinfec-
tion with hepatitis C virus (HCV) worsens neurological
functioning regardless of HIV infection status [59-61].
Subjects with other inflammatory diseases such as sys-
temic lupus erythematosus (SLE) [62] and rheumatoid
arthritis (RA) [63] have also been shown to exhibit a
high frequency of neurological disturbances. Interest-
ingly, all the above stated disorders are associated with a
peripheral type I IFN profile. While no direct correlative
analysis has been performed to assess the relationship
between peripheral activation and neurodysfunction in
SLE and RA despite the high frequency of occurrence,
our lab recently showed that the activation state of the
circulating monocytes in HIV/HCV coinfection correlates
with worsening neurocognitive symptoms [62,63,56].
Circulating monocytes traffic across the blood-brain
barrier (BBB) as part of a normal physiological process
to replenish the perivascular macrophages. However,
during specific inflammatory conditions, a subset of acti-
vated monocytes migrate across the BBB at a much
greater frequency and mediate events that ultimately
lead to neural cell dysfunction [64]. In the context ofuntreated HIV infection, such transmigration is widely
associated with spread of infection to the CNS, and
release of neurotoxic pro-inflammatory cytokines from ac-
tivated monocytes [65]. However, in the post-antiretroviral
therapy (ART) era, neurocognitive impairment continues
to persist and may be attributed to other mechanisms be-
side active viral infection [66-71]. The incidence of impair-
ment is worsened during coinfection with HCV, a classical
hepatotropic virus. While some studies have suggested
that HIV can establish a silent reservoir in the monocytes
despite successful viremic control, virus can be inter-
mittently activated and contribute to HAND [65,72,73].
The occurrence of neurocognitive difficulties in certain
non-infectious, inflammatory autoimmune disorders af-
fecting the periphery however suggests that perhaps
other mechanism (s) may also contribute to brain dys-
function (Figure 2).
Primary human monocytes have been shown to shed
exosomes in vitro as well as in vivo [5,21]. In fact, the
majority of the extracellular vesicles found to circulate
in the body are shed by platelets and mononuclear cells
[5]. Inflammatory signals from the environment can trig-
ger a change in the gene expression and miRNA profile
of a cell as well as in the exosomes shed by it. Given that
cells release exosomes under both physiological as well
as pathological conditions, monocyte-derived vesicles
could serve as a vehicle to transport neurotoxic cargo
to neural cells or alternatively trigger several signaling
pathways by virtue of ligands and receptors on the exo-
somal surface [74]. Dysregulated miRNAs, or mRNA
transcripts packaged into exosomes could be function-
ally delivered to neural cells and disrupt an array of
pathways within the cell, ultimately causing disturbances
in brain function. In addition, microbes that infect and
replicate in monocyte/macrophages, for instance HIV,
may release viral proteins or genomic products in exo-
somes and elicit an inflammatory response in recipient
neural cells. This phenomenon has been shown to occur
in T cells infected with HIV [18,26] as well as HCV-
infected hepatoma cells [75].
While monocyte/macrophages-derived exosomes can
function as a ‘Trojan horse’, exosomes in circulation
can also migrate across the BBB and exert a biological
effect on neural cells by internalizing the vesicles and
releasing exosomes in the CNS, as suggested by Alvarez-
Erviti et al. [76].
Exosomes for treating neuroinflammatory disorders
One of the major hurdles in treating neuroinflammatory
disorders has been the lack of an optimized delivery
strategy that allows the drug to cross the BBB. Exosomes
have the potential to serve as the ‘ideal drug delivery
vehicle’ owing to their desirable properties such as low
immunogenicity, ability to effectively transport a range
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and importantly, amenability to manipulation for per-
sonalized medicine.
The concept that exosomes can be packaged with
therapeutic agents and used for treating inflammatory
conditions in vivo was first demonstrated by Sun et al.
[77]. The study showed that exosomes loaded with curcu-
min, an anti-inflammatory naturally-occurring polyphenol,
not only increased the bioavailability and stability of the
compound in vivo, but also significantly improved survival
in lipopolysaccharide (LPS)-induced septicemia. Building
on this finding, Zhang et al. [78] later showed that LPS-
induced brain inflammation in mice could be alleviated by
intranasal administration of curcumin-loaded exosomes.
The exosomes were selectively internalized by microglial
cells and subsequently induced apoptosis in the activated
recipient cells.
Exosomes can be manipulated ex vivo to carry not just
therapeutic drugs but also short interfering RNAs (siR-
NAs) targeted against specific genes in the brain [79].
siRNAs are small non-coding RNA sequences that sup-
press gene expression by degrading the complementary
mRNA transcript. Alvarez-Erviti et al. [76] demonstrated
that exosomes from self-derived dendritic cells suppressed
target genes in the brain by the delivery of siRNA to neu-
rons, microglia and oligodendrocytes. The exosomes were
targeted specifically to neural cells by transfection of den-
dritic cells with Lamp2b, an exosomal membrane protein
fused to a rabies glycoprotein peptide. The authors also
showed that exosomes could be loaded directly with
siRNAs by electroporation and gene expression could
be silenced in the CNS by intravenous injection of the
vesicles. The latter observation suggests that exosomes
in the periphery can cross the BBB and regulate brain
function. Thus, exosomes have the potential to serve as
a non-invasive intervention for the successful delivery
of therapeutic agents to the brain.
Although the proof-of-concept studies are very en-
couraging, we are only beginning to understand the po-
tential of exosomes as a viable therapeutic intervention
for several hard-to-treat medical conditions. A few key
considerations for the development of exosome-based
therapies to treat neurological disorders are likely to re-
volve around: 1) specificity to achieve targeted delivery,
2) bioavailability and half-life of the exosomes in vivo in
order to determine frequency of administration, 3) site
of exosome administration and 4) potential toxicity asso-
ciated with non-targeted effects.
Exosomes as biomarkers for neuroinflammation
Changes in the cellular environment often impact the
content of exosomes shed by the cell. This phenomenon
has the potential to extend the application of these nano-
vesicles as biomarkers for various pathological conditionswherein specific proteins/mRNAs and/or miRNAs that
are altered in a diseased state can be detected in exosomes
for early diagnosis. Indeed, Banigan et al. [35] recently
showed that exosomal miRNAs recovered from post-
mortem prefrontal cortices of subjects diagnosed with
schizophrenia and bipolar disorders were different from
matched controls. Brain tissue samples from schizo-
phrenic patients had significantly elevated levels of exo-
somal miR-497 while those from bipolar disorder had
upregulation of miR-29c. Future studies focused on
identifying disease-associated exosomal miRNAs in the
CSF of living patients will perhaps validate the utility of
exosomes to serve as biomarkers in schizophrenia and
bipolar disorder. Apart from exosomal miRNAs, mRNA
transcripts differentially packaged into exosomes released
from diseased cells have also been proposed as biomarker
candidates. Skog et al. [80] demonstrated that subjects
with glioblastoma had detectable levels of vesicle-
associated epidermal growth factor receptor (EGFRvIII)
transcript in the serum that could be amplified by RT-
PCR. No amplification of the transcript was detected in
vesicles isolated from healthy subjects. Interestingly, this
variant of EGFR is specific to tumors and its specific
detection only in vesicles isolated from cancer patients
makes this transcript a good biomarker candidate.
Conclusions
The relevance of exosomes in the pathogenesis of several
CNS disorders has only begun to be explored. Given
their ability to mediate intercellular communication be-
tween cells, it is not surprising that exosomes represent
one of the key players in transporting neurotoxic cargo
and disseminating disease in the brain. Nevertheless, the
potential of exosomes to be manipulated for the trans-
port of therapeutic agents has generated heightened
interest in the field, as these vesicles are capable of
circumventing the major hurdles that are associated with
the delivery of drugs across the BBB.
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